Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy
10.3760/cma.j.issn.0253-3766.2017.03.007
- VernacularTitle: 高敏感格拉斯哥评分对进展期胃癌患者新辅助化疗疗效和预后的预测作用
- Author:
Yao CUI
1
;
Jian LI
2
;
Yanghui CAO
2
;
Mingyue LIU
1
;
Zuxuan SHI
1
;
Tianhui GAO
1
Author Information
1. Department of Oncology, Henan Provincial People′s Hospital (Zhengzhou University People′s Hospital), Zhengzhou, Henan 450003, China
2. Department of General Surgery, Henan Cancer Hospital, Zhengzhou University, Zhengzhou, Henan 450008, China
- Publication Type:Clinical Trail
- Keywords:
Gastric neoplasms;
High-sensitivity modified Glasgow Prognostic Score (HS-mGPS);
Neoadjuvant chemotherapy;
Treatment outcome;
Prognosis
- From:
Chinese Journal of Oncology
2017;39(3):195-200
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the predictive and prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) on the effect of neoadjuvant chemotherapy for advanced gastric cancer.
Methods:117 patients with advanced gastric cancer received neoadjuvant chemotherapy with SOX (oxaliplatin+ S1) or mFOLFOX 6(oxaliplatin+ CF+ 5-FU) regimen. HS-mGPS was calculated according to blood C-reactive protein (CRP) concentration and serum albumin (ALB) level. The correlation between HS-mGPS and clinicopathological characteristics was determined and the predictors of survival were analyzed.
Results:117 patients with stage ⅡB (43 cases), stage Ⅲ (60), and stage Ⅳ (14) received preoperative neoadjuvant chemotherapy. The overall response rate of neoadjuvant chemotherapy was 61.5%(72/117), and the tumor control rate was 88.0% (103/117), with a pathological response rate of 91.5% (107/117). The R0 resection rate was 81.2% (95/117). The median disease-free survival (DFS) was 21.0 (95% CI 6.4-35.6) months. The median overall survival (OS) was 39.0 (95% CI 21.4-56.6) months. Higher HS-mGPS was associated with higher T stage, local lymph-node metastasis, distant metastasis, lower chemotherapy overall response rate and lower pathological response rate (all P<0.05). The univariate analysis and multivariate analysis showed that higher HS-mGPS, presence of local lymph-node metastasis and non R0 resection were associated with poorer DFS and OS (P<0.05).
Conclusion:HS-mGPS can be used to predict the benefits of neoadjuvant chemotherapy and as an independent prognostic factor for survival in patients with advanced gastric cancer.
